Spero Therapeutics (NASDAQ: SPRO) saw its stock decline by 6.78% in after-hours trading to $2.20, after reporting Q2 2025 financial results.
The company exceeded earnings expectations with a net loss of $0.03 per share against an anticipated loss of $0.38, and posted revenues of $14.19 million, marking a 39.7% year-over-year increase.
The stock fell from a close of $2.36 at the end of regular trading, with a trading volume of 512.10 thousand shares.
